-
The net profit of 5 pharmaceutical companies in the first quarter of 2022 entered the "1 billion club" for the first time
Time of Update: 2022-08-11
Click to enter the exhibition pageRecently, while listed companies have disclosed their 2021 annual reports, their performance in the first quarter of 2022 has also been gradually announced .
-
Announcement of the first batch of national drug standards for traditional Chinese medicine formula granules
Time of Update: 2022-08-11
. In order to ensure the scientificity, rationality and applicability of the standards, opinions from all walks of life are solicited on the publicity of the national drug standards for the above-mentioned traditional Chinese medicine formula granules (see the annex for details) .
-
The per capita annual salary of pharmaceutical companies in 2021 will exceed 160,000 yuan, and 4 companies will increase their salary by more than 100%
Time of Update: 2022-08-11
Flush iFinD data shows that the per capita annual salary of 442 listed pharmaceutical companies will reach 168,300 yuan in 2021, an increase of 12.
Flush iFinD data shows that the per capita annual salary of 442 listed pharmaceutical companies will reach 168,300 yuan in 2021, an increase of 12.
-
The enthusiasm for ADC drug development is high, and another pharmaceutical company ADC innovative drug has been granted priority review qualification by the FDA
Time of Update: 2022-08-11
Huadong Medicine stated that Mirvetuximab Soravtansine is a FRα-targeted ADC drug, and it is also a key product under development in the company's innovative tumor drug pipeline .
-
In-depth analysis of the procurement volume of the two major alliances, centralized procurement forces the rational admission of traditional Chinese medicine imitation
Time of Update: 2022-08-11
New entrants cut prices for the market It can be seen from the centralized procurement rules of the Hubei Regional Alliance and the Guangdong Regional Alliance for the centralized procurement of Chinese patent medicines that if the generic varieties of traditional Chinese medicines want to compete for the market, it is difficult to obtain the procurement volume of medical institutions at the beginning .
-
The back waves of the children's medicine potential track are strong
Time of Update: 2022-08-10
On the one hand, the information of children's drug labeling needs to be supported by scientific research evidence ; Some company leaders believe that "children's clinical research is the current bottleneck restricting the development of children's medicine in China .
-
The sixth batch of collection results was carried out in many places, and tens of millions of diabetic patients will use affordable insulin
Time of Update: 2022-08-10
[Pharmaceutical Network Industry News] At the end of April, the National Medical Insurance Administration and other two departments issued the "Notice on Improving the National Organization of Drugs (Insulin Special) Centralized Procurement and Use of Supporting Measures", requiring the selected products of insulin centralized procurement to be selected in each province.
-
Ten consecutive boards, daily limit tide!
Time of Update: 2022-08-10
Zhongsheng Pharmaceutical On the evening of May 11, Zhongsheng Pharmaceutical issued an announcement that the clinical trial registration application of Zhongsheng Ruichuang oral anti-new coronavirus 3CL protease inhibitor, a class of innovative drugs, RAY1216 tablets, was accepted by the State Food and Drug Administration.
-
Illustration of network security and informatization construction of drug supervision "14th Five-Year Plan"
Time of Update: 2022-08-10
The "Plan" clarifies: implement the drug supervision concepts of risk governance, responsibility governance, whole-process governance, and smart governance, adhere to systematic thinking, make full use of the results of regulatory scientific research, innovate regulatory methods and methods, improve regulatory systems and mechanisms, and promote the integration of information technology and business development.
-
TOP12 global rare disease drugs in 2021: K drug sales of US$17.18 billion, BMS two blockbuster drugs ranked in the top three
Time of Update: 2022-08-10
12Jakafi In late 2011, Jakafi became the first JAK inhibitor approved by the FDA for the treatment of the bone marrow disease myelofibrosis .
The drug's active ingredient, lenalidomide, is a new-generation derivative of thalidomide with immunomodulatory, anti-angiogenic and anti-tumor properties Revlimid is a blockbuster immunomodulator obtained after Bristol-Myers Squibb acquired Celgene.
-
More than half of the traditional Chinese medicine companies are profitable, and the net profit of 5 companies has increased by more than 100%
Time of Update: 2022-08-10
009 billion yuan, a year-on-year increase of 343% Conba: Net profit rose by more than 343% According to Conba's annual report, in 2021, it will achieve operating income of 6.
-
The development of the Chinese medicine industry continues to improve, and the export market of Chinese herbal medicines and Chinese patent medicines is constantly expanding
Time of Update: 2022-08-10
2% For example, according to customs statistics, in the first quarter of this year, the total import and export value of Chinese medicinal materials and Chinese patent medicines in Bozhou City was 140 million yuan, a decrease of 0.
-
The national insulin special centralized procurement landed in Qinghai, an average drop of 48%
Time of Update: 2022-08-10
89 yuan per vial, depending on the patient It is estimated that using 6 sticks per month can save about 4,200 yuan in medication costs for a year, and the average daily cost is as low as less than 4 yuan Eli Lilly's Protamine Zinc Recombinant Insulin Lispro Mixed Injection (25R), 3ml: 300 units (pre-filled), which has the largest drop in centralized procurement, has dropped from an average of 80.
-
The State Pharmacopoeia Commission solicits proposals for the implementation of "green environmental protection" pharmaceutical excipient standards
Time of Update: 2022-08-10
On May 6, the official website of the State Pharmacopoeia Committee issued a notice to solicit suggestions on the implementation of "green environmental protection" pharmaceutical excipient standards
-
Which pharmaceutical company lays off employees?
Time of Update: 2022-08-10
Among them, three foreign-funded pharmaceutical companies, Arcadia Healthcare, AlerisLife, and Brookdale Senior Care, will lay off more than 10,000 employees, which will decrease respectively.
Among them, three foreign-funded pharmaceutical companies, Arcadia Healthcare, AlerisLife, and Brookdale Senior Care, will lay off more than 10,000 employees, which will decrease respectively.
-
TIGIT research and development has been setback!
Time of Update: 2022-08-10
The leading pharmaceutical companies are obviously unwilling to miss the next market opportunity in the "post-PD-1 era", and are scrambling to expand the "circle of friends" by waving banknotes ": In October 2020, AstraZeneca announced a collaboration with Arcus Biosciences to initiate a registrational Phase 3 clinical trial evaluating Arcus' investigational anti-TIGIT antibody domvanalimab (AB154) in combination with the PD-L1 inhibitor Imfinzi (durvalumab) in Africa.
-
The promotion meeting of the special rectification work of drug safety was held
Time of Update: 2022-08-10
On May 30, the State Food and Drug Administration held a promotion meeting for the special rectification of drug safety, summed up the work of the special rectification of drug safety in the previous stage , exchanged and shared the experience of various places, and promoted the whole system to carry out the special rectification of drug safety in depth .
-
Chia Tai Tianqing introduced it!
Time of Update: 2022-08-10
LAG3 mAb in Phase II clinical trials in ChinaInsight database Global rights and interests Insight database of LAG-3 monoclonal antibody Sym022 Global new drug module LAG-3 is the third immune checkpoint to achieve commercialization in the world after PD-1 and CTLA-4, and has been shown in PD-1 combination therapy Excellent curative effect .
-
In 2022, a large number of pharmaceutical companies will accelerate their exit!
Time of Update: 2022-08-10
[Pharmaceutical Network Industry News] On May 17, the Jinan Administrative Examination and Approval Service Bureau issued an announcement on the cancellation of the "Drug Business License" (Retail) (No. 20220022), according to relevant regulations, including Shandong Zhiyaotang Pharmaceutical Chain Co.
-
Under the general trend of innovation, a number of new drugs have been introduced recently
Time of Update: 2022-08-10
, and further develop, register, manufacture and sell the target product zirconium Zr 89 crefmirlimab berdoxam in China For example, a few days ago, Dongcheng Pharmaceutical announced that its wholly-owned subsidiary Andico and ImaginAb, Inc. formally signed the "License Agreement".
